Mycoplasma Testing Market By Product Type (Instruments, Kits & Reagents, Services); By Technology (PCR-Based, ELISA-Based, Culture-Based); By Application (Biopharmaceutical Production, Clinical Diagnostics, Academic Research); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Mycoplasma Testing Market : How Biopharma Quality Risk and Clinical Diagnostics Are Expanding Repeat Testing Demand

The Global Mycoplasma Testing Market was valued at USD 980 million in 2024 and is projected to reach USD 1.78 billion by 2030, expanding at a 10.4% CAGR during the forecast period

 

The market is expanding because mycoplasma testing now protects two commercially important areas: biological product quality and patient diagnosis.

 

In biopharma, the test reduces the risk of contaminated cell cultures, delayed batch release, repeated production work, and avoidable quality failures. In healthcare, it supports diagnosis of respiratory and sexually transmitted infections where delayed detection can increase treatment uncertainty and patient-management costs.

 

Mycoplasma testing is not only an occasional laboratory check. It is becoming a routine safeguard across biopharmaceutical production, mycoplasma testing in cell culture, clinical diagnostics, and research quality control.

 

Biopharmaceutical Production Leads as Quality Failure Creates Direct Economic Exposure

Biopharmaceutical production accounts for 53.0% of the Mycoplasma Testing Market in 2024, equal to USD 519.4 million. By 2030, the segment is estimated to reach 55.0% share, equal to USD 979.0 million.

This segment leads because biologics, vaccines, cell therapies, and gene therapies carry high production value and strict release expectations. A contamination event can delay product release, waste manufacturing capacity, and disrupt supply planning. For manufacturers, mycoplasma testing is therefore not just a compliance activity; it is a risk-control expense that protects product value and manufacturing continuity.

FDA CBER approved 17 biologics license applications and 26 BLA supplements in 2024. This level of biologics activity supports recurring demand for quality-control testing as approved products and manufacturing updates move through regulated production environments.

Cell and gene therapy strengthens this demand base. FDA lists 49 licensed cellular and gene therapy products as of April 23, 2026. These products increase the need for reliable testing because production delays can affect both revenue realization and patient access to high-value therapies.

 

Kits & Reagents Dominate Because Mycoplasma Testing Is a Repeat Purchase Market

Kits & reagents account for 60.0% of market revenue in 2024, equal to USD 588.0 million. By 2030, the segment is estimated to reach 63.0% share, equal to USD 1,121.4 million.

This product category leads because every test consumes materials. Instruments support the testing environment, but mycoplasma testing kits, reagents, controls, and assay materials are purchased repeatedly. As laboratories test more frequently, the revenue pool naturally shifts toward recurring consumables.

ATCC reports that mycoplasma contamination affects 15%–35% of continuous cell cultures and at least 1% of primary cell cultures. This supports a clear economic reason for routine testing: contamination can waste materials, delay studies, disrupt production planning, and create repeat-work costs.

Instruments account for 18.0% of the market in 2024, equal to USD 176.4 million, and are forecast to reach USD 284.8 million by 2030. Instruments remain necessary, but they do not repeat at the same purchasing frequency as kits and reagents.

Services account for 22.0% of the market in 2024, equal to USD 215.6 million, and are forecast to reach USD 373.8 million by 2030. Service demand is supported by biopharma companies, academic labs, and smaller manufacturers that prefer outsourced testing when internal capacity, validation workload, or quality staffing is limited.

 

PCR-Based Testing Gains Share as Faster Decisions Reduce Cost and Clinical Uncertainty

PCR-based testing accounts for 58.0% of market revenue in 2024, equal to USD 568.4 million. By 2030, it is estimated to reach 66.0% share, equal to USD 1,174.8 million.

In biopharma, faster testing can reduce waiting time before product release. In clinical diagnostics, faster results can help physicians make treatment decisions with more confidence. This is why demand is shifting toward PCR-based mycoplasma testing and Mycoplasma PCR Detection Kit formats across both production and healthcare settings.

CDC states that nucleic acid amplification tests are the preferred diagnostic method for Mycoplasma pneumoniae infections, and that multiple FDA-cleared tests can detect the infection. This supports PCR-based adoption because healthcare laboratories need diagnostic methods that fit patient-care timelines.

Culture-based testing accounts for 27.0% of the market in 2024, equal to USD 264.6 million, and is forecast to reach USD 356.0 million by 2030 while declining to 20.0% share. Culture-based methods remain relevant in selected reference and compliance settings, but their share declines where buyers place higher value on faster decisions.

ELISA-based testing accounts for 15.0% of the market in 2024, equal to USD 147.0 million, and is forecast to reach USD 249.2 million by 2030. The segment remains useful in selected diagnostic workflows, but it captures less growth than PCR-based testing because speed and repeatability carry stronger commercial value.

 

Clinical Diagnostics Expands as Mycoplasma Testing Supports Better Patient Management

Clinical diagnostics accounts for 32.0% of the market in 2024, equal to USD 313.6 million. By 2030, the segment is estimated to reach 35.0% share, equal to USD 623.0 million.

This application is gaining importance because mycoplasma infections can create avoidable healthcare burden when diagnosis is delayed. Testing helps clinicians identify infections that may not respond well to standard treatment assumptions, reducing uncertainty in care pathways.

CDC estimates that 2 million Mycoplasma pneumoniae infections occur each year in the United States. The healthcare relevance became more visible in 2024, when Mycoplasma pneumoniae-associated community-acquired pneumonia among hospitalized children reached 12.5 per 1,000 hospitalizations, compared with 2.1 during 2018–2023.

Mycoplasma genitalium adds a second clinical demand channel. CDC states that it causes 15%–20% of nongonococcal urethritis and 40% of persistent or recurrent urethritis. This gives diagnostic laboratories a clear role in supporting targeted care when patients experience persistent symptoms or repeated treatment failure.

 

Academic Research Remains Necessary, but Commercial Spending Shifts Toward Biopharma and Diagnostics

Academic research accounts for 15.0% of the market in 2024, equal to USD 147.0 million. By 2030, it is estimated to reach USD 178.0 million, although its share declines to 10.0%.

Research institutions continue to need mycoplasma testing in cell culture because contamination can compromise study quality, delay early-stage discovery work, and increase project costs. However, academic research has lower spending intensity than biopharmaceutical manufacturing and clinical diagnostics.

The difference is economic. Research labs test to protect experimental integrity. Biopharma manufacturers test to protect product release and revenue timing. Clinical laboratories test to support patient care. The stronger financial impact in biopharma and healthcare diagnostics explains why academic research grows in value but loses market share.

 

Mycoplasma PCR Test Cost Becomes a Total-Cost Decision, Not a Per-Test Price Question

The market should not be assessed only through the visible price of a single mycoplasma PCR test. Buyers evaluate the broader cost of delayed batch release, repeated cell culture work, outsourced testing, failed experiments, and unresolved clinical cases.

This is why kits & reagents capture 60.0% of 2024 revenue and PCR-based testing captures 58.0%. The spending pattern shows that laboratories are paying for repeatable decision-making, not just a single test result.

For suppliers, this makes recurring consumables, validated kits, outsourced services, and workflow support commercially important. For buyers, the value lies in reducing preventable losses across production, research, and patient-care settings.

 

North America Leads as Biopharma Scale and Clinical Testing Demand Reinforce Each Other

North America accounts for 42.0% of the market in 2024, equal to USD 411.6 million, and is forecast to reach USD 712.0 million by 2030.

The region leads because it combines high-value biologics manufacturing, commercial cell and gene therapy activity, advanced clinical diagnostics, and strong quality expectations. Mycoplasma testing demand comes from both sides of the market: regulated product release and patient diagnosis.

This dual demand base gives North America the strongest revenue position. Laboratories and manufacturers in the region are paying to reduce product-release risk, support diagnostic confidence, and maintain continuity across biopharma and healthcare delivery.

 

Europe Holds a Compliance-Led Position as Standards Shape Buyer Decisions

Europe accounts for 28.0% of market revenue in 2024, equal to USD 274.4 million, and is estimated to reach USD 480.6 million by 2030.

Europe’s market is shaped by medicine-quality expectations and compliance-led purchasing. EDQM adopted revisions to European Pharmacopoeia chapter 2.6.7 Mycoplasmas and 11 related monographs in 2025. This matters commercially because manufacturers and laboratories must keep testing choices aligned with updated standards.

For suppliers, Europe rewards products and services that reduce compliance risk. For buyers, the priority is not only test availability; it is confidence that testing supports product release, audit readiness, and uninterrupted supply.

 

Asia Pacific Gains Share as Vaccine Supply, Biomanufacturing, and Diagnostics Expand

Asia Pacific accounts for 22.0% of the market in 2024, equal to USD 215.6 million. By 2030, it is estimated to reach 25.0% share, equal to USD 445.0 million.

The region gains share because vaccine supply, biologics production, and diagnostic access are expanding together. Mycoplasma testing benefits when healthcare systems strengthen laboratory capacity and when manufacturers increase biological production.

WHO’s 2024 vaccine market report covers 88 vaccine products sold through 207 countries and procurement channels by 116 manufacturers. This scale shows why quality assurance has become a global healthcare supply issue. As Asia Pacific becomes more connected to vaccine and biologics supply, mycoplasma testing demand follows.

 

Latin America and Middle East & Africa Remain Smaller but Linked to Public Health Supply

Latin America accounts for 5.0% of the market in 2024, equal to USD 49.0 million, and is forecast to reach USD 89.0 million by 2030. Middle East & Africa accounts for 3.0% in 2024, equal to USD 29.4 million, and is forecast to reach USD 53.4 million by 2030.

These regions have smaller revenue shares because advanced biopharma production and high-volume molecular testing networks are less concentrated. However, vaccine procurement, imported biologics, reference laboratories, and public health supply chains keep the market relevant.

UNICEF delivered 2.787 billion vaccine doses to 99 countries in 2024. This shows why quality assurance remains important even in regions with smaller local testing infrastructure. For these markets, demand is often linked to public health supply, outsourced testing, and reliable access to quality-assured biological products.

 

Market Outlook: Commercial Value Lies in Reducing Risk, Delay, and Diagnostic Uncertainty

The Mycoplasma Testing Market is forecast to rise from USD 980 million in 2024 to USD 1.78 billion by 2030. The strongest revenue pools are expected in kits & reagents, PCR-based testing, biopharmaceutical production, and clinical diagnostics.

The market’s long-term value lies in reducing avoidable cost and healthcare uncertainty. In biopharma, testing helps reduce the risk of failed batches and delayed release. In clinical diagnostics, it supports better patient management for respiratory and STI-related infections. In research, it protects study quality and project budgets.

This is why mycoplasma testing is becoming a recurring healthcare and biomanufacturing expense. Buyers are not only paying for detection. They are paying for confidence, continuity, and lower risk across production and patient care.

 

Mycoplasma Testing Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 980 Million
Revenue Forecast in 2030	USD 1.78 Billion
Overall Growth Rate	CAGR of 10.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, Technology, Application, Geography
By Product Type	Instruments, Kits & Reagents, Services
By Technology	PCR-Based Testing, ELISA-Based Testing, Culture-Based Testing
By Application	Biopharmaceutical Production, Clinical Diagnostics, Academic Research
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, UK, China, India, South Korea, Brazil, South Africa, UAE
Market Drivers	- Surging demand for biologics production - Stringent regulatory compliance for contamination control - Rapid shift to high-sensitivity PCR-based testing
Customization Option	Available upon request